{"id":19809,"date":"2023-07-06T13:29:57","date_gmt":"2023-07-06T13:29:57","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19809"},"modified":"2024-08-21T13:48:03","modified_gmt":"2024-08-21T13:48:03","slug":"precisionlife-establishes-strategic-cns-drug-development-collaboration-with-nanopharmaceutics","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/precisionlife-establishes-strategic-cns-drug-development-collaboration-with-nanopharmaceutics\/","title":{"rendered":"PrecisionLife establishes strategic CNS drug development collaboration with Nanopharmaceutics"},"content":{"rendered":"
\n

\r\n\"Bio-Rad<\/a>\r\n<\/p>\n<\/div><\/section><\/div>

<\/p>\n<\/div><\/section>
\n

PrecisionLife establishes strategic CNS drug development collaboration with Nanopharmaceutics<\/h1>\/ in E-News<\/a>, Therapeutic Drug Monitoring<\/a> <\/span><\/span><\/header>\n<\/div><\/section>
\n

PrecisionLife, a leading techbio company driving precision medicine into complex chronic diseases, and Nanopharmaceutics, a clinicalstage pharmaceutical development company, have established a strategic collaboration aiming to accelerate and de-risk the development of Nanopharmaceutics\u2019 portfolio of central nervous system (CNS) assets.<\/h3>\n

<\/p>\n

The collaboration will leverage PrecisionLife\u2019s proprietary combinatorial analytics platform to analyze patient genomic profiles and identify target-specific genetic biomarkers for each of Nanopharmaceutics\u2019 CNS drug development programmes. These biomarkers will be based on combinations of single nucleotide polymorphisms (SNPs) specifically associated with Nanopharmaceutics\u2019 drugs\u2019 mechanisms of action and the development indication.<\/p>\n<\/div><\/section>
\n

\"\"<\/div><\/div><\/div>
\n

As part of the collaboration, PrecisionLife will support Nanopharmaceutics in the clinical development of their CNS programmes by identifying patient stratification biomarkers to link the development compounds\u2019 mechanisms of action to the patient subgroups with the highest likelihood of demonstrating positive outcomes in clinical trials, optimizing patient selection. The terms of the collaboration also include an option for Nanopharmaceutics to negotiate an exclusive right to the patient stratification biomarkers discovered through the PrecisionLife platform.<\/p>\n

This precision medicine approach has the potential to significantly increase the probability of clinical trial success rates, even in the most complex chronic diseases. Beyond the applications set out in this collaboration, PrecisionLife biomarkers may also serve as invaluable complementary diagnostic tools, expediting the approval of new therapeutic products and facilitating the swift delivery of the latest medicines to patients with unmet medical needs.<\/p>\n

This collaboration between PrecisionLife and Nanopharmaceutics marks a significant milestone in the pursuit of precision medicine for complex chronic diseases, by using mechanistic patient stratification biomarkers to inform clinical trial design and transform the lives of patients.<\/p>\n<\/div><\/section>
\n